Shelton Capital Management Decreases Stock Position in Boston Scientific Co. (NYSE:BSX)

Shelton Capital Management lowered its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 16.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 153,819 shares of the medical equipment provider's stock after selling 30,056 shares during the quarter. Shelton Capital Management's holdings in Boston Scientific were worth $13,739,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. TFC Financial Management Inc. raised its position in Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the period. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 152 shares in the last quarter. Global Wealth Strategies & Associates raised its holdings in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 250 shares during the period. West Oak Capital LLC acquired a new position in Boston Scientific during the 4th quarter worth about $29,000. Finally, Valley National Advisers Inc. boosted its holdings in Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 286 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 12,000 shares of the firm's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total value of $1,265,760.00. Following the completion of the sale, the director now owns 24,398 shares in the company, valued at $2,573,501.04. This trade represents a 32.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now owns 25,443 shares in the company, valued at $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,183 shares of company stock worth $13,948,476 over the last 90 days. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

BSX has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a report on Monday, December 16th. Argus set a $130.00 target price on Boston Scientific in a report on Tuesday, February 18th. Royal Bank of Canada upped their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday, March 3rd. Finally, StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $109.04.

Boston Scientific Stock Performance

NYSE:BSX traded up $1.02 during trading hours on Friday, reaching $93.66. 8,303,541 shares of the company's stock were exchanged, compared to its average volume of 6,356,881. The company has a 50-day moving average of $100.54 and a 200 day moving average of $94.10. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $138.53 billion, a price-to-earnings ratio of 74.93, a P/E/G ratio of 2.79 and a beta of 0.73.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.